Home > Insider Trading > Filing (0000950142-10-000403)

Filing Details

Accession Number:: 0000950142-10-000403
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-10 12:00:00
Reporting Period:: 2010-03-08

Filing Date:: 2010-03-10
Accepted Time:: 2010-03-10 18:50:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1401923	Map Pharmaceuticals Inc.	MAPP	Pharmaceutical Preparations (2834)	200507047

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
900203	George Soros	888 Seventh Ave 31St Flr New York NY 10106	No	No	Yes	No
1029160	Soros Fund Management Llc	888 Seventh Avenue 31St Floor New York NY 10106	No	No	Yes	No
1387524	Robert Soros	C/O Soros Fund Management Llc 888 Seventh Avenue, 31St Floor New York NY 10106	No	No	Yes	No
1387590	Allan T Jonathan Soros	C/O Soros Fund Management Llc 888 Seventh Avenue, 31St Floor New York NY 10106	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-03-08	3,155	$14.61	2,843,875	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2010-03-08	81,416	$14.61	2,843,875	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2010-03-09	634	$15.40	2,826,875	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2010-03-09	16,366	$15.40	2,826,875	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.20 to $14.80. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, SFM Participation, L.P ("SFM Participation"), a managing member of Perseus-Soros Partners, as well as Biotech Management Partners, LLC ("Biotech Management Partners") and Quantum Industrial Partners, LDC ("QIP").
Perseus-Soros Partners is the general partner of Perseus-Soros. SFM Participation is a managing member of Biotech Management Partners and Perseus-Soros Partners. SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is SFM LLC. SFM LLC also serves as the principal investment manager to QIP. Mr. George Soros ("Mr. Soros") serves as Chairman of SFM LLC, Mr. Robert Soros ("Robert Soros") serves as Deputy Chairman of SFM LLC and Mr. Jonathan Soros ("Jonathan Soros") serves as President and Deputy Chairman of SFM LLC.
Represents 3,155 shares of the Issuer's Common Stock sold by SFM Participation. After the sale, SFM Participation owns directly 634 shares of the Issuer's Common Stock.
Represents 81,416 shares of the Issuer's Common Stock sold by QIP. After the sale QIP, owns directly 17,072 shares of the Issuer's Common Stock.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.70 to $15.56 The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Represents 634 shares of the Issuer's Common Stock sold by SFM Participation. After the sale, SFM Participation owns directly no shares of the Issuer's Common Stock.
Represents 16,366 shares of the Issuer's Common Stock sold by QIP. After the sale, QIP owns directly 706 shares of the Issuer's Common Stock.